10.07.2015 Views

Cornea - ARVO

Cornea - ARVO

Cornea - ARVO

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>3% diquafosol ophthalmic solution (P=0.478) and after instillation of2% rebamipide ophthalmic suspension. (P=0.234).Conclusions: Quantitative serial measurement of forward lightscattering and HOAs showed that the temporal reduction in opticalquality may be mainly attributed to increased forward light scatteringafter instillation of 2% rebamipide ophthalmic suspension and 3%diquafosol ophthalmic solution, and increased HOAs after instillationof high viscosity 0.3% sodium hyaluronate ophthalmic solution innormal subjects.Commercial Relationships: Shizuka Koh, Santen, Inc. (R),Johnson & Johnson (R), Topcon (R), Otsuka Pharmaceutical Co. (R);Naoyuki Maeda, Topcon (F), Santen (R), Otsuka (R), Oculus (R),HOYA (R); Chikako Ikeda, Rohto pharmaceutical CO.,LTD. (E);Yoshihiro Takai, Rohto Pharmaceutical Co. Ltd (E); HisatakaFujimoto, None; Yoshinori Oie, Santen (F), HOYA (F); TakeshiSoma, HOYA corporation (R), Santen Pharmaceutical Co., Ltd (F),Otsuka Pharmaceutical Co., Ltd (F); Motokazu Tsujikawa, Shionogi& Co. (C), Daiichi Sankyo Co. (F), Daiichi Sankyo Co. (R), SantenCo. (R), AMO Co. (R); Kohji Nishida, Alcon (C), Alcon (F), HOYA(F), Senju (F), Pfizer (F), Santen (F), Osaka University (P)Support: Grants-in-Aid for Scientific Research from the JapaneseMinistry of Education, Culture, Sports, Science and Technology.(No. 22791659)Program Number: 6006 Poster Board Number: A0069Presentation Time: 10:30 AM - 12:15 PMEffects of diquafosol sodium eye drops on tear film stabilitySeika Den 1 , Hiroyuki Iseda 1 , MURAT DOGRU 1, 2 , Jun Shimazaki 1, 2 .1 Ophthalmology, Tokyo Dental College, Chiba, Japan;2 Ophthalmology, Keio University School of Medicine, Tokyo, Japan.Purpose: To investigate the effects of diquafosol sodium eye drops(DQS), a purinergic P2Y2 receptor agonist, on tear film stability inpatients with unstable tear film.Methods: Two prospective studies were conducted. One was anexploratory non-randomized trial on 39 eyes with dry eye symptomsand short tear film break-up time (BUT), but without epithelialdamage. Schirmer’s test value was not considered as an inclusion orexclusion criterion. Changes in questionnaire and Visual AnalogScale (VAS) scores for symptoms, BUT, Schirmer’s value, andfluorescein staining scores of the cornea and conjunctiva werestudied for 3 months. The other was a randomized clinical trial (RCT)of DQS and artificial tears in 17 eyes with short BUT. Eyes withdecreased Schirmer’s values (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!